{"entity":{"id":"paper-icc-2022-arber-blood-2022","kind":"paper","name":"International Consensus Classification of myeloid neoplasms and acute leukaemias (2022)","aka":[],"tldr":"A parallel classification to the WHO 2022 edition from an international expert group, which among other changes creates an MDS/AML category for 10 to 19 percent blasts and gives TP53-mutated disease its own entities.","summary":"Classification of myeloid neoplasms and acute leukaemias integrating morphology, clinical features and genomics, produced by the International Consensus Classification group, with new categories for MDS/AML, TP53-mutated myeloid neoplasms and genetically defined AML subtypes at lower blast thresholds.","asOf":"2026-09-17","links":[{"label":"Blood 2022","url":"https://doi.org/10.1182/blood.2022015850"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/35767897/"}],"tags":[],"related":[],"cancers":["mds-higher-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood"],"dependsOn":[],"notes":[],"journal":"Blood","year":2022,"doi":"10.1182/blood.2022015850","pmid":"35767897","authors":"Arber DA, Orazi A, Hasserjian RP, et al.","paperType":"guideline","findings":[],"whatItMeans":"Trial eligibility and risk stratification in AML and MDS often refer to this classification alongside the WHO edition; the two overlap heavily but not completely.","caveats":["Coexists with the WHO fifth edition, so the same marrow may carry two names."],"changedPractice":true},"route":"/key-papers/paper-icc-2022-arber-blood-2022/","neighbours":{"cancer":[{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"}],"journal":[{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/"}]}}